Several investment management firms have increased their stakes in Medtronic PLC, resulting in an optimistic view on the stock. The firm has experienced a price dip, but analysts like Jim Cramer argue this is a good thing, stating "everything they've been doing lately is right." It's clear, however, that potential investors should factor in the information that Medtronic's stock is down 11.5% following their last earnings report.
Positive news includes the FDA's approval for the firm's Stealth AXiS Surgical System and the strong second and third quarter fiscal results leading to the highest enterprise revenue growth in 10 quarters. Medtronic has experienced success in growing its diabetes and cardiovascular operations, while its acquisition of Scientia Vascular strengthens its neurovascular offer.
Conversely, Medtronic reduced its earnings outlook due to updates on MiniMed, and weak financial prospects seem to be dragging the stock down. There has been significant bearish options activity, despite Medtronic's long-term growth outlook. They also downgraded earnings outlook as MiniMed Flex’s funding and IPO diluted earnings.
Medtronic Plc MDT News Analytics from Tue, 19 Aug 2025 07:00:00 GMT to Sat, 04 Apr 2026 10:42:04 GMT - Rating 6 - Innovation 3 - Information 8 - Rumor -5
